Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry.

Aim: Examine the effects of baseline hypertension (HTN) and statin or proton pump inhibitor (PPI) use on sunitinib treatment outcomes in STAR-TOR, a real-world registry. Materials & methods: Presence or absence of HTN and use or nonuse of statins or PPIs were determined at registry entry. End points included overall survival (OS) and progression-free survival (PFS). Results: Data were from 557 patients. Presence or absence of HTN did not affect OS or PFS. PFS (median [95% CI]) was longer in statin users (9.4 [6.5-13.6] months) versus nonusers (6.9 [5.7-8.2] months) (p = 0.0442). OS was shorter in PPI users (20.2 [14.9-28.3] months) versus nonusers (25.7 [22.7-33.0] months) (p = 0.0212). Conclusion: Comorbidities and comedications may affect real-world sunitinib treatment outcomes. ClinicalTrials.gov identifier: NCT00700258.

Future oncology (London, England). 2020 Oct 06 [Epub ahead of print]

Martin Boegemann, Katrin Schlack, Michael Rink, Stephan Bernhardt, Michael Moran, Marcus Hubbe, Lothar Bergmann, Marianne Schmid, Arne Strauss

Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Germany, and West German Cancer Center, University Hospital of Muenster, Muenster, Germany., Klinik und Poliklinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany., Pfizer Pharma GmbH, Berlin, Germany., Medizinische Klinik 2, Universitätsklinikum Frankfurt, Frankfurt, Germany., Klinik für Urologie, Universitätsmedizin Göttingen, Göttingen, Germany.